ArticleJournal of inflammation research2026
Integrated Multi-Omics Profiling Identifies CD84-Associated Microglial Alterations in Focal Cortical Dysplasia Type II.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Focal cortical dysplasia type II (FCDII) is a major cause of drug-resistant epilepsy in children, yet its molecular pathogenesis remains poorly characterized. Accumulating evidence has underscored the critical role of persistent neuroinflammatory activity in the pathogenesis of focal cortical dysplasia. Methods: We employed an integrated multi-omics approach to dissect the molecular pathology of FCDII. This included data-independent acquisition mass spectrometry (DIA-MS) proteomics and re-analysis of public transcriptomic datasets. Differential expression analysis, protein-protein interaction (PPI) network construction, and hub gene identification were performed. Key findings were validated using quantitative real-time PCR (qPCR) and further investigated through analysis of single-cell RNA sequencing (scRNA-seq) data to resolve cellular heterogeneity and cell-cell communication. Results: Proteomic profiling of FCDII tissue identified 460 differentially expressed proteins (DEPs) enriched in cortical development, cytoskeletal organization, and immune-inflammatory signaling. Protein-protein interaction (PPI) network analysis further prioritized several hub molecules, among which the pro-inflammatory glycoprotein CD84 exhibited consistent upregulation across both proteomic and transcriptomic datasets. Single-cell analysis revealed that CD84 expression was preferentially localized to a microglial subpopulation characterized exhibiting elevated inflammation-related signatures, with particularly prominent enrichment in FCDIIB samples. CD84-positive microglia also demonstrated increased predicted interactions with astrocytes, neurons, and endothelial cells through signaling pathways involving colony-stimulating factor (CSF), CX3C motif chemokine, macrophage migration inhibitory factor (MIF), and somatostatin-related signaling. Conclusion: Our multi-omics approaches suggest a potential role for CD84 in influencing microglial inflammatory states and in shaping their predicted interactions with astrocytes, neurons, and endothelial cells in FCDII. These findings offer preliminary molecular clues that may inform future mechanistic investigations of microglial alterations in this disorder.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.